Lifesci Nerd Out [#11]
Reads from April 2026
1. Peptides: the science is real but the hype cycle is moving faster than evidence
Read:
This piece breaks peptides down with far more nuance than the wellness internet typically offers. Peptides are short chains of amino acids, but grouping them together as one “health trend” is misleading. Some, like insulin or GLP-1s, are clinically validated therapeutics; others are marketed aggressively despite limited human data.
The article’s biggest contribution is separating medically proven peptides from gray-market compounds, especially as consumer demand surges around anti-aging, weight loss, and performance optimization.
Key insight:
Peptides may represent the next major category where consumer health enthusiasm outpaces regulatory and scientific literacy.
2. India’s biotech challenge isn’t talent, it’s structural capital
Mazumdar-Shaw argues India’s requirement for revenue track records before IPO eligibility is fundamentally misaligned with biotech, where companies often spend years in R&D before commercialization. Her broader thesis: India doesn’t lack scientific capability—it lacks financial pathways designed for life sciences innovation.
Key insight:
Without pre-revenue biotech capital structures, India risks staying a manufacturing powerhouse rather than becoming a frontier biotech ecosystem.
3. AI is changing who gets to participate in biomedical problem-solving
Read:
This piece centers around a deeply personal mission: using AI tools, biomedical research, and open scientific systems to better understand and potentially impact treatment pathways for a loved one’s brain tumor.
The broader implication is powerful: AI is lowering barriers to information access, hypothesis generation, and scientific participation.
Key insight:
Biotech may increasingly shift from institution-only participation to AI-augmented independent agency.
4. Eroom’s Law still looms over biotech but discovery efficiency matters differently for startups
Read:
One of my favorite substack talks about why biotech innovation remains economically difficult despite technological advances. While large pharma is burdened by clinical and commercialization costs, startups are often constrained by discovery quality, translational success, and early-stage target validation.
Key insight:
AI’s biggest value may not simply be faster discovery, it may be improving probability-adjusted biology and making early-stage biotech more viable.
5. Frontier founders are increasingly building infrastructure, not just products
Read:
This article argues that the smartest founders are increasingly focused on infrastructure: observability, orchestration, trust layers, workflow optimization, and enterprise systems rather than just visible consumer-facing products.
Key insight:
In frontier sectors, infrastructure often becomes the hidden value layer.
6. Semaglutide may be reshaping more than weight, it could alter alcohol consumption behavior
Read:
This piece explores emerging evidence and growing public interest around semaglutide’s potential effects beyond weight loss—particularly its possible role in reducing alcohol cravings or changing drinking behavior. The article examines how GLP-1 receptor agonists, originally designed for metabolic conditions, may influence reward pathways tied to addiction and compulsive behaviors.
While the science is still developing, the broader implication is significant: a blockbuster obesity drug class may also intersect with behavioral health categories like alcohol use disorder, opening questions around new therapeutic markets, off-label curiosity, and how metabolic drugs may influence broader lifestyle patterns.
Key insight:
Semaglutide may represent a larger pharmaceutical shift where metabolic therapies begin crossing into behavioral and addiction-related health outcomes, potentially redefining how one drug class impacts multiple public health challenges.
7. Longevity is expanding fast but the movement may be drifting from science into excess
Read:
This piece examines how the modern longevity movement, once centered on extending healthspan through credible science is increasingly at risk of spiraling into hype, optimization obsession, and commercial overreach. As more founders, influencers, and consumers chase biomarkers, supplements, and extreme protocols, longevity can start to shift from evidence-based prevention toward a culture of endless intervention.
The article raises a core tension: while advances in aging science are real, the market surrounding longevity is growing faster than consensus around what meaningfully improves long-term health. The result is a space where aspiration, fear of aging, and commercialization can blur scientific rigor.
Key insight:
Longevity may remain one of healthcare’s biggest opportunities but without stronger scientific grounding, it risks becoming a sector where optimization culture outpaces actual evidence.
If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.